Company Overview and News

KLCI slips below 1,800 level as sellers outpace buyers

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719

KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

Construction landscape likely to remain challenging

2018-09-13 theedgemarkets
Construction sector Maintain neutral: For the recent second quarter of 2018 results season, seven (54%) out of the 13 contractors under our coverage reported core earnings that were below expectations and six (46%) were within. Contractors are cushioned by healthy order-book levels following the robust job flows in the past two years amid the challenging near-term industry landscape.
9571 5263 9679 BSMAF 8311 1818

Pesona Metro likely to face slowing macro job flow outlook

2018-09-06 theedgemarkets
Pesona Metro Holdings Bhd (Sept 5, 35 sen) Maintain hold with a higher target price (TP) of 32 sen: Pesona Metro Holdings Bhd announced that it had been awarded a new contract from TA Global Bhd worth RM264.3 million for the construction of serviced apartment in Bandar Sri Damansara, Petaling Jaya.
5158 8311

KLCI pares loss, poised to extend lacklustre run

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI pared some of its loss at the midday break today, but looked poised to extend its lacklustre start in September.
HLFBF APEXF PBLOF 7090 SPMXF 7036 1082 5681 BATS 4162 0162 1295 8311 6033 5199 PNADF SPMXY 3026 3301 1368 HIPEF PNAGF

Stock With Momentum: Pesona Metro Holdings

2018-09-05 theedgemarkets
Pesona Metro Holdings Bhd (-ve) Trading in shares of Pesona Metro Holdings Bhd (fundamental: 0.45/3, valuation: 1.4/3) triggered our momentum algorithm yesterday for the second time this week.

KLCI remains in the red, down 0.52% in line with region

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI remained in the red at mid-morning and was down 0.52%, in line with the weaker regional markets.
HLFBF APEXF 7173 PBLOF 7090 4065 7036 1082 BATS 4162 0162 1295 8311 6033 PNADF 0104 2216 5819 PNAGF 3719

Pesona Metro shares boosted by contract win

KUALA LUMPUR: Pesona Metro Holdings Bhd is up 4.41% in early trade Wednesday to 35.5 sen, its highest level since March 30.
5158 8311

Trading ideas: IJM, Pesona Metro, Borneo Aqua, Sapura Energy

KUALA LUMPUR: JF Apex expects IJM Corp Bhd , Pesona Metro Holdings Bhd , Borneo Aqua Harvest Bhd and Sapura Energy Bhd to be among the stocks to watch on Wednesday.
5158 8311 0098

KLCI seen drifting sideways, defend 1,800-level

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI is seen drifting sideways today, in line with the weaker overnight close at most global markets.
7007 1368 8311 0098

IJM Corp, Pesona Metro, Borneo Aqua, Ark Resources, Sapura Energy and UEM Edgenta

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Sept 5) may include the following: IJM Corp Bhd, Pesona Metro Holdings Bhd, Borneo Aqua Harvest Bhd, Ark Resources Bhd, Sapura Energy Bhd and UEM Edgenta Bhd
7007 1368 5158 8311 0098

Pesona Metro secures RM264.3mil job

KUALA LUMPUR: Pesona Metro Holdings Bhd (PMHB) has secured a RM264.3mil construction project from Indo Aman Bina Sdn Bhd, a wholly-owned subsidiary of TA Global Bhd .
5158 BSMAF 8311 1818

Pesona Metro bags RM264.3m construction job

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): Pesona Metro Holdings Bhd's unit has secured a contract worth RM264.3 million to build two blocks of serviced apartments in Bandar Sri Damansara, Selangor.
5158 8311

KLCI poised to close lower for fourth day

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI looked poised to close lower for the fourth consecutive day and maintain its poor start to September at midday break today, tracking losses at regional markets.
UPBMF 7113 TPGVF BATS 4162 5168 2089 8311 7123 5199 7079 3522 TGLVY 3026 3301 3867 6888 5819 AXXTF 2836 HIPEF HRGHY

KLCI remains in the red as select blue chips drag

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI remained in negative zone at mid-morning today, dragged by losses at select index-linked blue chips.
UPBMF 8621 6432 BATS 4162 2089 5014 8311 5199 7079 7617 KLKBY 5029 2445 4588 4456 3026 6888 MYPRY AXXTF HIPEF 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...